z-logo
open-access-imgOpen Access
T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
Author(s) -
Borchmann Peter,
Moccia Alden,
Greil Richard,
Herzberg Mark,
Fosså Alexander,
Hüttmann Andreas,
Keil Felix,
Dierlamm Judith,
Schaub Valdete,
Hänel Mathias,
Novak Urban,
Meissner Julia,
Hellmuth Johannes,
Mathas Stephan,
Zijlstra Josée. M.,
Viardot Andreas,
Hertenstein Bernd,
Martin Sonja,
Giri Pratush,
Kreissl Stefanie,
Fuchs Michael,
Schneider Gundolf,
Rosenwald Andreas,
Klapper Wolfram,
Eich Hans Theodor,
Baues Christian,
Hallek Michael,
Kobe Carsten,
Diehl Volker,
Engert Andreas
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000890576.23258.1c
Subject(s) - medicine , brentuximab vedotin , etoposide , vincristine , clinical endpoint , dacarbazine , randomized controlled trial , cyclophosphamide , oncology , regimen , surgery , lymphoma , chemotherapy , hodgkin lymphoma

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here